Key Takeaways

A pill form of semaglutide did not slow Alzheimer’s in two large trials

The drug was safe but did not slow disease progression

Results haven’t been peer-reviewed yet

TUESDAY, Nov. 25, 2025 (HealthDay News) — A pill version of semaglutide, the ingredient in Ozempic and Wegovy , did not slow the progress of Alzheimer’s disease , drugmaker Novo Nordisk announced Monday.

In two Phase 3 trials, researchers tested an oral form of semaglutide in more than 3,800 adults with Alzheimer’s who were already receiving standard care.

While the drug was safe and improved some biological markers linked to the disease, it did not slow memory or cognitive decline compared to a placebo.

Novo Nordisk said results from the trials have not yet been peer-reviewed or published, but will

See Full Page